Category Archives: market

business, finance, market, real estate, technology

WeWork India to launch ₹3,000cr IPO on October 3

Leave a comment

**WeWork India to Launch ₹3,000 Crore IPO on October 3**

*By Dwaipayan Roy | September 28, 2025, 03:12 PM*

WeWork India, a leading player in the co-working space, is all set to launch its initial public offering (IPO) on October 3, 2025. The IPO is estimated to be worth around ₹3,000 crore. According to the red herring prospectus (RHP), bidding for anchor investors will open on October 1 for one day, and the IPO will close on October 7.

### Share Details and Offer for Sale (OFS)

The upcoming IPO from WeWork India is structured as an Offer for Sale (OFS) of up to 4.63 crore equity shares. The shares will be sold by Embassy Buildcon LLP, a promoter group firm, and Ariel Way Tenant Ltd, a subsidiary of WeWork Global. Since this is an OFS, WeWork India itself will not receive any proceeds from the listing.

### About WeWork India

Established in 2017, WeWork India operates under an exclusive license of the global ‘WeWork’ brand. The company is promoted by the Bengaluru-based real estate giant Embassy Group, which currently holds about 76.21% stake in WeWork India. WeWork Global owns the remaining 23.45%.

WeWork India operates across major Tier-1 cities, including Bengaluru, Mumbai, Pune, and Hyderabad, among others.

### Business Scale and Operations

WeWork India manages an extensive portfolio of over 77 lakh sq ft of commercial space, with 70 lakh sq ft currently operational. The company offers a desk capacity of more than 1.03 lakh and employs over 500 people nationwide.

In January 2024, WeWork India raised ₹500 crore through a rights issue aimed primarily at reducing debt and supporting its growth plans.

### Market Entry and IPO Goals

The company’s plan to list its equity shares on the stock exchanges in early October is intended to enhance its market visibility, provide liquidity to existing shareholders, and establish a public market for its shares in India.

With the IPO opening on October 3 and closing on October 7, WeWork India is expected to make its stock market debut by October 10.

—

Stay tuned for more updates on WeWork India’s IPO and its journey in the listed space.
https://www.newsbytesapp.com/news/business/everything-we-know-about-wework-india-s-ipo/story

business, health, investment, market

Indian pharma, healthcare firms eye ₹13,000cr via IPOs

Leave a comment

The industry plans to raise an estimated ₹12,000–13,000 crore over the next six to nine months. According to data compiled by *The Economic Times*, around 15 companies from this sector are likely to enter the primary market soon.

**Market Activity: SEBI Receives DRHPs for Several Companies**

The Securities and Exchange Board of India (SEBI) has received draft red herring prospectuses (DRHPs) from several companies. Notably, Indira IVF refiled in July with an issue size of about ₹3,500 crore, while Sahajanand Medical Technologies filed for a ₹1,500 crore issue. Other significant filings include NephroPlus (approximately ₹2,000 crore), Molbio Diagnostics (₹200 crore), and Cotec Healthcare (₹500 crore).

**Fundraising Plans: Companies That Have Received SEBI’s Nod**

Among the companies that have secured SEBI’s approval are Rubicon Research, aiming to raise ₹1,085 crore, and Corona Remedies, planning to raise ₹800 crore. Additionally, other companies gearing up for initial public offerings (IPOs) include Paramesu Biotech (₹600 crore), Allchem Lifesciences (₹190 crore), Paras Healthcare (about ₹900 crore), Veeda Clinical Research (around ₹500 crore), and Gujarat Kidney and Superspeciality Hospital (₹128 crore). Genetix Biotech is also poised to file for an IPO soon.

**Trends: ART Sector Attracting Investor Interest Due to Strong Fundamentals**

Saurav Chaube, a research analyst at Samco Securities, highlighted a strategic shift in the assisted reproductive technology (ART) sector. He explained that growing investor interest is fueled by strong market fundamentals, such as increasing infertility awareness and favorable demographics.

Chaube further noted that companies like Indira IVF and Gaudium IVF have filed through the confidential route. This approach signals a maturing market where players seek to optimize their public offerings while minimizing early scrutiny and potential opportunist litigation.

**Industry Outlook: Pharma and Healthcare Increasingly in Focus Since COVID-19**

Samir Bahl, CEO of Anand Rathi Advisors, observed that global markets have increasingly concentrated on pharma and healthcare since the COVID-19 pandemic. He pointed out that countries like the US and India are ramping up investments in pharmaceutical and biotech innovation.

Bahl also remarked that Indian pharma companies are commanding high price-to-earnings ratios, reflecting favorable valuations and strong investor interest in the sector.
https://www.newsbytesapp.com/news/business/15-pharma-healthcare-firms-to-launch-ipos-in-coming-months/story